Sino Biopharmaceutical Limited
SBMFF
$0.9891
$0.03914.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.01B | 3.93B | 3.85B | 3.77B | 3.71B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.01B | 3.93B | 3.85B | 3.77B | 3.71B |
| Cost of Revenue | 741.73M | 568.56M | 394.54M | 383.63M | 375.49M |
| Gross Profit | 3.27B | 2.54B | 1.81B | 1.74B | 1.69B |
| SG&A Expenses | 1.69B | 1.32B | 949.74M | 921.18M | 899.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 862.42M | 619.85M | 376.12M | 361.50M | 349.43M |
| Total Operating Expenses | 3.29B | 3.17B | 3.04B | 2.98B | 2.94B |
| Operating Income | 717.99M | 766.14M | 813.19M | 790.44M | 770.85M |
| Income Before Tax | 733.03M | 617.41M | 501.23M | 469.62M | 441.12M |
| Income Tax Expenses | 68.28M | 76.71M | 85.17M | 78.30M | 71.93M |
| Earnings from Continuing Operations | 664.75 | 540.71 | 416.06 | 391.32 | 369.19 |
| Earnings from Discontinued Operations | 219.13M | 220.98M | 222.84M | 122.13M | 20.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -398.17M | -309.53M | -220.45M | -213.50M | -208.08M |
| Net Income | 485.71M | 526.48M | 566.85M | 448.35M | 330.21M |
| EBIT | 717.99M | 766.14M | 813.19M | 790.44M | 770.85M |
| EBITDA | 851.00M | 700.24M | 736.36M | 722.48M | 712.49M |
| EPS Basic | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 73.17B | 73.52B | 55.35B | 55.50B | 55.66B |
| Average Diluted Shares Outstanding | 73.18B | 73.53B | 73.84B | 74.00B | 74.15B |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | -- | -- | -- | -- | -- |